Protagonist Therapeutics to Present New Rusfertide Study Data at EHA Congress 2024

Protagonist Therapeutics, Inc. announced its plans to present additional findings from the rusfertide Phase 2 REVIVE study at the upcoming European Hematology Association Congress in Madrid. The congress is scheduled to run from June 13 to June 16, 2024. The data will focus on an oral presentation detailing updated long-term results of rusfertide in treating patients with polycythemia vera.

Representing Protagonist, Kristen M. Pettit, MD, will provide insights into the use of rusfertide for maintaining hematocrit control and reducing the need for therapeutic phlebotomy. The oral presentation will take place on June 14th, 2024. Another significant presentation will discuss the absence of QTc prolongation in healthy subjects after treatment with rusfertide, led by Nishit Modi, SVP of Clinical Pharmacology at Protagonist Therapeutics.

Together, these studies highlight the potential benefits and safety of rusfertide, a hepcidin mimetic, for patients with polycythemia vera. These presentations are part of continued efforts to investigate and verify rusfertide's efficacy and safety in clinical settings.